FDA places hold on Epizyme's tazemetostat

Epizyme Inc. (NASDAQ:EPZM) fell $2.90 (19%) to $12.40 in after-hours trading Monday after FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma during a Phase I pediatric trial of the selective inhibitor of enhancer of zeste homolog 2 (EZH2).

The hold suspends new enrollment in U.S. clinical trials of tazemetostat. Patients already enrolled who have not experienced disease progression may continue to receive tazemetostat...